Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Clearance Models: Noncompartmental Models

Clearance Models: Noncompartmental Models

Clearance is a pharmacokinetic parameter traditionally defined by compartment models, signifying the rate at which a drug is expelled from the body. However, a noncompartmental model offers an alternative method for assessing clearance, primarily employing empirical data obtained after administering a single drug dose.
The noncompartmental approach capitalizes on extensive sampling data, correlating the volume of distribution to systemic exposure and the administered dosage. This method enables...

One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

One-Compartment Open Model for IV Bolus Administration: Estimation of Clearance

Clearance is a key pharmacokinetic parameter that quantifies the volume of body fluid from which a drug is entirely removed within a specific time frame. It is crucial in assessing how a drug is eliminated from the body and has critical clinical applications.
In the one-compartment open model for intravenous (IV) bolus administration, clearance is estimated by dividing the elimination rate by the plasma drug concentration. This equation leverages the elimination rate constant and the apparent...

One-Compartment Open Model: Urinary Excretion Data and Determination of k

One-Compartment Open Model: Urinary Excretion Data and Determination of k

The one-compartment open model leverages urinary excretion data to estimate renal clearance, which gauges the kidney's capacity to expel a drug. This method offers several benefits, including directly measuring drug elimination and assessing the kidney's contribution to overall drug clearance. However, this approach has limitations. It assumes sole renal excretion of the drug, which is not true for all drugs. Accurate urinary excretion and plasma drug concentration measurement can also be...

Two-Compartment Open Model: Extravascular Administration

Two-Compartment Open Model: Extravascular Administration

The two-compartment model for extravascular administration represents a drug's absorption and distribution process. It features a central compartment, where the drug is first absorbed, and a peripheral compartment, which illustrates the drug's distribution throughout the body. The rate of change in drug concentration in the central compartment is calculated by three exponents: absorption, distribution, and elimination.
The absorption exponent (ka) indicates the speed at which the drug is...

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated from...

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The FDA Roadmap to Reducing Animal Testing in Preclinical Safety Studies: Where Will It Lead Us?

Clinical pharmacology in drug development·2026

Same author

Bemnifosbuvir and ruzasvir in combination exhibit potent synergistic antiviral activity in vitro while maintaining a favorable nonclinical safety profile in vivo.

Antiviral research·2025

Same author

Stronger together: a cross-SIG perspective on improving drug development.

Journal of pharmacokinetics and pharmacodynamics·2025

Same author

Asia-inclusive drug development leveraging principles of ICH E5 and E17 guidelines: Case studies illustrating quantitative clinical pharmacology as a foundational enabler.

Clinical and translational science·2024

Same author

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.

The Lancet. Oncology·2024

Same author

Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report.

Clinical lung cancer·2024

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

Estimation of human drug clearance using multiexponential techniques.

Kosalaram Goteti¹, Patrick J Brassil, Steven S Good

¹Department of Drug Metabolism and Pharmacokinetics, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, MA 02451;

Journal of Clinical Pharmacology

|June 19, 2008

Summary

A new multiexponential allometry (MA) method accurately predicts human drug clearance from preclinical data. This approach improves upon simple allometry, showing better accuracy and reducing outliers in drug development predictions.

More Related Videos

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Related Experiment Videos

Last Updated: Jul 4, 2026

Comprehensive Analysis of Drug Response using the FLICK Assay

Comprehensive Analysis of Drug Response using the FLICK Assay

Published on: June 6, 2025

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Area of Science:

Pharmacokinetics
Drug Development
Biomedical Engineering

Background:

Predicting human drug clearance from preclinical data is crucial for drug development.
Existing allometric methods have limitations in accuracy and outlier reduction.

Purpose of the Study:

To develop and validate a multiexponential allometry (MA) method for predicting human drug clearance.
To compare the predictive performance of MA against simple allometry (SA).

Main Methods:

Utilized separate human and preclinical species data sets for clearance prediction.
Employed the MA equation: CL = aBWb + cBWd, deriving constants from preclinical pharmacokinetic data.
Assessed prediction accuracy and percentage outliers for MA and SA.

Main Results:

MA demonstrated superior prediction accuracy for human drug clearance compared to SA.
MA predicted human clearances within approximately 10% of a 3-fold error margin.
Monkey was identified as a key species for scaling, with MA performing better when SA slope > 0.7.

Conclusions:

Multiexponential allometry (MA) offers a more accurate method for predicting human drug clearance from preclinical studies.
The MA method effectively reduces prediction errors and outliers, enhancing its utility in drug development.
Incorporating data from specific species like the monkey can further improve the reliability of MA predictions.